CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD58 改变通过诱导弥漫性大 B 细胞淋巴瘤中的 PDL1 和 IDO 调控抗肿瘤免疫应答

CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma.

T 细胞急性淋巴细胞白血病的 CAR-T 细胞治疗

Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.

抗 CD22 CAR-NK 细胞治疗高效杀伤淋巴瘤细胞

High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.

儿童非霍奇金淋巴瘤治疗中的 CAR-T 细胞疗法

CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.

CD19/CD22 双特异性嵌合抗原受体 NK-92 细胞的开发与评价

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.

CD22 重定向 CAR NK-92 细胞对 B 细胞淋巴瘤的免疫治疗

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells.

我们的数据显示，过继转移 m971-BBZ NK-92 细胞可作为 B 细胞淋巴瘤免疫治疗的一种有前景的策略。

儿童、青少年及年轻成人非霍奇金淋巴瘤的细胞与体液免疫治疗

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.

儿童和青少年癌症患者 CAR-T 细胞药物研发儿科战略论坛：ACCELERATE 与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i